Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$91.90

2.11 (2.35%)

14:36
12/07/17
12/07
14:36
12/07/17
14:36

Sage Therapeutics price target raised to $225 from $140 at Chardan

Chardan analyst Gbola Amusa raised his price target for Sage Therapeutics to $225 cting the positive top-line results from the Phase II trial of SAGE-217 in moderate-to-severe major depressive disorder. Importantly, the beneficial effects of SAGE-217 were reported as soon as the morning following the first dose, the analyst tells investors in a research note. He believes this further demonstrates the "rapid effect" of SAGE-217 compared to standard treatments for major depressive disorder. He sees the data as a "step in the direction of blockbuster sales" and keeps a Buy rating on Sage.

  • 07

    Dec

SAGE Sage Therapeutics
$91.90

2.11 (2.35%)

12/07/17
ADAM
12/07/17
NO CHANGE
Target $191
ADAM
Buy
Canaccord ups Sage target to $191 on 'unequivocally positive' data
Canaccord Genuity analyst John Newman raised his price target for Sage Therapeutics to $191 from $140 after the company reported Phase II trial results for SAGE-217 in major depressive disorder. The stock in early trading is up 66%, or $60.86, to $152.76. The data are "unequivocally positive" with a statistically significant effect versus placebo after the first dose, Newman tells investors in a research note. By comparison, currently marketed selective serotonin reuptake inhibitor depression drugs often take months to show an effect, the analyst points out. Further, he views SAGE-217's safety as "clean" and "highly encouraging." While admitting some investors may want to take profits on today's profits, Newman thinks Sage's long-range prospects are positive and he maintains a Buy rating on the shares.
12/07/17
LEER
12/07/17
NO CHANGE
Target $246
LEER
Outperform
Sage Therapeutics price target raised to $246 from $123 at Leerink
12/07/17
RBCM
12/07/17
NO CHANGE
Target $280
RBCM
Outperform
Sage Therapeutics price target raised to $280 from $137 at RBC Capital
12/07/17
RBCM
12/07/17
NO CHANGE
Target $280
RBCM
Top Pick
RBC puts Street-high price target of $280 on Sage Therapeutics
RBC Capital analyst Brian Abrahams raised his price target for Sage Therapeutics to $280 from $137 after the company reported Phase II trial results for SAGE-217 in major depressive disorder. The target represents the high among Wall Street sell-side analysts, according to Bloomberg. The "outstanding" data show a "differentiated profile that could be game-changing" if replicated in Phase III, and may lead to $3.8B in out-year sales, Abrahams tells investors in a research note. The analyst still sees "considerable fundamental upside" in shares despite today's rally. He also sees a "good likelihood" of takeout at a valuation premium to current levels. Abrahams keeps an Outperform rating on Sage Therapeutics. The stock in midday trading is up 78%, or $72.10, to $164.00.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.